Amarantus Re-acquires Rights to Alzheimer's Blood
Post# of 30067
(Total Views: 473)
Posted On: 04/06/2018 10:14:35 AM
Amarantus Re-acquires Rights to Alzheimer's Blood Diagnostic LymPro Test
Company also re-acquires remaining rights to MS diagnostic MSPrecise
San Francisco, CA and New York, NY -- April 5, 2018 -- InvestorsHub NewsWire -- Amarantus Bioscience Holdings, Inc. (OTC Pink: AMBS) (the "Company" or AMBS), a US-based JLABS-alumnus biotechnology holding company developing first-in-class orphan neurologic, regenerative medicine and ophthalmic therapies through its subsidiaries, today announced that it has re-acquired all rights held by Avant Diagnostics, Inc. (OTC Pink: AVDX) to neurology-focused diagnostic tests LymPro Test, MSPrecise and NuroPro. Under the terms of the agreement, Amarantus agreed to cancel all liabilities (approximately $722,500) Avant owed to Amarantus and issue Avant 1,000,000 shares of Amarantus common stock. Avant agreed to issue to Amarantus an additional 30,092,073 Avant common shares in satisfaction of certain amounts owed under the original acquisition agreement. Amarantus intends to assign these diagnostic assets to a new subsidiary that aligns with Amarantus' holding company business model.
"The science underpinning the LymPro Test for Alzheimer's disease has continued to mature during the intervening period of our ownership by virtue of the improved understanding of the immune system's involvement in the underlying mechanisms of cell death in Alzheimer's disease," said Gerald Commissiong, President & CEO of Amarantus. "Going forward, we believe there is an opportunity to move the neurology assets via a focused subsidiary and key additions to management with experience to take it forward. We continue to be excited by Avant's Theralink platform and its potential to dramatically improve cancer prescription accuracy, both in terms of positive and negative predictive value, using its industry leading proprietary Reverse-Phase Protein Array (RPPA) platform that evaluates phospho-protein activation in tumor tissue."
https://ih.advfn.com/p.php?pid=nmona&article=77124333
Company also re-acquires remaining rights to MS diagnostic MSPrecise
San Francisco, CA and New York, NY -- April 5, 2018 -- InvestorsHub NewsWire -- Amarantus Bioscience Holdings, Inc. (OTC Pink: AMBS) (the "Company" or AMBS), a US-based JLABS-alumnus biotechnology holding company developing first-in-class orphan neurologic, regenerative medicine and ophthalmic therapies through its subsidiaries, today announced that it has re-acquired all rights held by Avant Diagnostics, Inc. (OTC Pink: AVDX) to neurology-focused diagnostic tests LymPro Test, MSPrecise and NuroPro. Under the terms of the agreement, Amarantus agreed to cancel all liabilities (approximately $722,500) Avant owed to Amarantus and issue Avant 1,000,000 shares of Amarantus common stock. Avant agreed to issue to Amarantus an additional 30,092,073 Avant common shares in satisfaction of certain amounts owed under the original acquisition agreement. Amarantus intends to assign these diagnostic assets to a new subsidiary that aligns with Amarantus' holding company business model.
"The science underpinning the LymPro Test for Alzheimer's disease has continued to mature during the intervening period of our ownership by virtue of the improved understanding of the immune system's involvement in the underlying mechanisms of cell death in Alzheimer's disease," said Gerald Commissiong, President & CEO of Amarantus. "Going forward, we believe there is an opportunity to move the neurology assets via a focused subsidiary and key additions to management with experience to take it forward. We continue to be excited by Avant's Theralink platform and its potential to dramatically improve cancer prescription accuracy, both in terms of positive and negative predictive value, using its industry leading proprietary Reverse-Phase Protein Array (RPPA) platform that evaluates phospho-protein activation in tumor tissue."
https://ih.advfn.com/p.php?pid=nmona&article=77124333
(7)
(0)